ask our doctors

Lymphoma B Cell

Get the facts on Lymphoma B Cell treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Lymphoma B Cell prevention, screening, research, statistics and other Lymphoma B Cell related topics. We answer all your qestions about Lymphoma B Cell.

Question: Is it possible to find quantification of cancerous B cells present over time in a B cell lymphoma patient? I have a teacher who gives really odd homework assignments... and it may help if I knew how quickly B cell lymphoma spread and how quickly rituximab destroys it. Thanks!

Answer: -It is possible to find quantification of cancerous B cells but it will be too much for homework ,better you pick other and do this later joining to medical college,your interest & confidence are good ,keep reading many books and thinking new Ideas,do not get discouraged because of teachers,understand thier moods,take it easy,you have bright scientific future


Lymphoma B Cell News

Nodal Marginal Zone B-Cell Lymphoma: A Diagnostic and Therapeutic Dilemma

Cancer Network
Nodal marginal zone B-cell lymphoma (NMZL) is a primary nodal B-cell lymphoma that shares morphologic, immunophenotypic, and genetic characteristics with extranodal marginal zone lymphoma (MZL) and splenic MZL, but without those specific localizations ...
 

Proactive Investors USA & Canada

Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL ...
Bradenton Herald
 

ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive ...

MarketWatch (press release)
The current clinical program includes a Phase 3 study in Diffuse Large B-Cell Lymphoma, and a trial to evaluate ZEVALIN in previously untreated follicular non-Hodgkin's lymphoma patients. "This study highlights a major advance for DLBCL and other ...
 

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to ...

Sacramento Bee
... Selecting Indication for Angiogenesis Affecting Drugs in Oncology 7109.1 Acute Lymphocytic Leukemia 7139.2 Acute Myelogenous Leukemia 7149.3 Adrenal Cancer 7179.4 B-cell Lymphoma 7189.5 Basal Cell Cancer 7199.6 Biliary Cancer 7209.7 Bladder Cancer ...
 

Immunomedics Awarded Broad Patent for Anti-CD20 and Anti-CD22 Combination Therapy

MarketWatch (press release)
The therapeutic compositions are of use for treating diseases such as B-cell malignancies, non-Hodgkin's lymphoma, indolent and aggressive forms of B-cell lymphoma, and acute and chronic forms of lymphatic leukemias. The patent provides coverage until ...
 

OneMedPlace Initiates Research Coverage on Biovest and BiovaxID(R ...

MarketWatch (press release)
... this week by Dr. Malini Chatterjee, Ph.D., discusses the anticipated regulatory pathway and market opportunity for BiovaxID(R), Biovest's personalized cancer vaccine for the treatment of certain B-cell subtypes of non-Hodgkin's lymphoma (NHL).
 

Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS(TM ...

MarketWatch (press release)
The data are being presented at the T-Cell Lymphoma Forum being held January 26-28, 2012 in San Francisco, CA. ADCETRIS is not approved for use in front-line mature T-cell lymphoma. -- The sequential treatment regimen comprises two cycles of ...
 

Another Year, Another High...

NASDAQ
A number of phase 1 and 2 studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. Last December, the company presented interim ...
 

Kansas City Star

Rockville's Micromet agrees to $1.16B takeover by Amgen
Gazette.Net: Maryland Community News Online
 

The Star-Ledger - NJ.com

Celgene to acquire Avila, posts strong earnings growth
Pharma Times